Age-Related Macular Degeneration

Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.

At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.

Presented at ASRS 2023, study data suggest aflibercept 8 mg provided greater therapeutic benefit, an extended injection interval, and equivalent safety versus aflibercept 2 mg in eyes with nAMD.

Experts discusses the unique challenges managing the care of patients with diabetic macular edema (DME).

Experts discuss prospective therapies and improved outcome targets for patients with neovascular age-related macular degeneration (nAMD).

A combination of baseline factors, early BCVA, and morphologic responses at 3 months only moderately predicted long-term BCVA responses in eyes with nAMD.

Low vision rehabilitation was associated with statistically significant increases in the overall composite score of a vision-related quality of life scale.

Experts discuss their experience using the treat and extend strategy with aflibercept and their clinical advice when administering treatment.

Experts discuss the long-term efficacy and safety of aflibercept in the treatment of neovascular age-related macular degeneration (nAMD).

Experts discuss the comparison of age-related macular degeneration treatments trials (CATT) and how today’s retina specialists can apply the results in their daily practice.

Experts discuss how they define suboptimal responders to anti-vascular endothelial growth factor (Anti-VEGF) treatment and how they manage the care of those patients.

A systematic review and meta-analysis revealed that combination therapy was associated with superior anatomical outcomes in all but 1 included study.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our June 2023 month-in-review features updates to the pipeline, diabetic eye disease news from ADA 2023, and promising data on the use of artificial intelligence.

Experts offer clinical advice on identifying and managing suboptimal responders on anti-vascular endothelial growth factor (Anti-VEGF) treatment.

Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).

Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).

Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.

Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.

Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

A systematic review and meta-analysis found no significant differences in visual and anatomical outcomes between ranibizumab biosimilars and reference ranibizumab in eyes with neovascular AMD.

In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, to discuss the recent FDA approval of pegcetacoplan (SYFOVRE™), the interplay between being a clinician and corporate executive, and how the retina landscape may change in the coming years.

Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

An analysis suggests biosimilar bevacizumab was safe and effective over 6 weeks with noted improvement in BCVA and OCT parameters for patients with macular edema.

An analysis based in Japan suggests ranibizumab biosimilar is dominant to other anti-VEGF treatments in patients with nAMD in both treat-and-extend and PRN regimens.

The analysis of the XPLORE trial suggested XSB-001 showed biosimilarity to reference ranibizumab as assessed by BCVA improvement at 8 weeks.

Results from the analysis suggest participants treated for previously diagnosed obstructive sleep apnea experience a significantly higher risk of having RPD coexistent with AMD.